NEW YORK (GenomeWeb) — GNS Healthcare has completed a $10 million Series C financing round, led by new investors including Celgene, Alexandria Real Estate Equities, and Gi Global Health Fund.
The new investors joined prior investors in the round, including Cambia Health Solutions, Heritage Provider Network, and Mitsui USA.
The firm said it would use the funds to accelerate its machine learning-based software for precision medicine, including new cloud-based data solutions.
"GNS solutions better match drugs and other health interventions to individual patients, improving outcomes and lowering costs related to preterm birth; medication non-adherence; metabolic syndrome; comparative effectiveness in diabetes, specialty care and oncology; end-of-life care; new member risk on healthcare exchanges; patient stratification in clinical trials; and more," the firm said in a statement.
The money is the first fundraising for GNS Healthcare since January 2014, when it completed a $10 million Series B round.
In September, the Cambridge, Massachusetts-based firm announced it would collaborate with the Multiple Myeloma Research Foundation on the Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile, or CoMMpass, study.